# US 2021/0276981 A1 · Covalent immune recruiter compounds for immune cell recognition and associated uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276981 A1
- Document ID: US20210276981A1
- Status: Published application
- Kind: A1
- Application number: 17/249,332
- Filed: 2021-02-26
- Published: 2021-09-09
- Earliest claimed: 2020-02-26
- Assignees: McMaster University
- Applicants: McMaster University
- Inventors: Anthony Rullo; Jonathan Bramson; Yonghong Wan; Benjamin Lake; Nickolas Semiuck
- Web page: https://patentgrep.com/patent/US20210276981A1

## CPC

- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 493/10: Spiro-condensed systems
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application relates to compounds of Formula I comprising an antibody binding domain (ABD) comprising a hapten that binds to an antibody in a subject, the antibody comprising a hapten binding site, an antibody labelling domain (ALD) comprising a functional group that forms a covalent bond with an amino acid in the antibody that is proximal to the hapten binding site and the formation of the covalent bond results in elimination of the ABD and either a target binding domain (TBD) or a detection moiety domain (DMD), each domain being optionally connected with independently selected linkers. The present application also includes methods and uses of the compounds, for example, for immune recognition of target cells by recruited labelled antibodies. ABD−(L1)n-ALD-(L2)m-R

## Claims

### Claim 1

A compound of Formula I or a pharmaceutically acceptable salt and/or solvate thereof:
ABD-(L1)n-ALD-(L2)m-R
wherein
ABD is an antibody binding domain comprising a hapten that binds to an antibody in a subject, the antibody comprising a hapten binding site;
ALD is an antibody labelling domain comprising a functional group that forms a covalent bond with an amino acid in the antibody that is proximal to the hapten binding site and the formation of the covalent bond results in elimination of the ABD;
L1 and L2 are, independently, linker groups;
n and m are, independently, 0 or 1; and
R is a target binding domain (TBD) or a detection moiety domain (DMD).

### Claim 2 (depends on 1)

The compound of claim 1, wherein the ABD comprises a hapten which binds to an antibody that is endogenous in the subject.

### Claim 3 (depends on 1)

The compound of claim 1, wherein ABD is
(1) a di- or trinitrophenyl group having the following structure:
wherein Y1 is H or NO2;
X1 is NR1, O, CH2, S(O), SO2, SO2O, OSO2 or OSO2O; and
R1 is H, C1-4alkyl or C(O)C1-4alkyl;
(2) a bicyclic nitro-substituted aromatic group having the following structure:
wherein X2 is a bond, O, CH2, NR2 or S; and
R2 is H, C1-4alkyl or C(O)C1-4alkyl;
(3) a galactose-containing carbohydrate having the following structure:
wherein X3 is CH2, O, NR3 or S;
R3 is H or C1-4alkyl; and
Z1 is a bond, monosaccharide, disaccharide, oligosaccharide, glycoprotein or glycolipid; or
(4) a group having the following structure:
wherein X4 is O, CH2 or NR4; and
R4 is H, C1-4alkyl or C(O)C1-4alkyl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein the ABD is:
wherein
Y1 is H or NO2;
X1 is NH or O;
X3 is O; and
Z1 is a bond, a monosaccaride or a disaccharide.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the DMD comprises a radiolabel, a fluorescent label, a spin label, isotope label, a positron emission tomography (PET) or a single-photon emission computed tomography label.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the DMD is
wherein f is an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 0, 1, 2, 3, 4, 5 or 6.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the TBD is
(1)
wherein a is an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 1, 2, 3, 4, 5 or 6;
(2)
wherein X5 and X6 are independently CH2, O, NH or S; and
b is an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 1, 2, 3, 4, 5 or 6;
(3)
wherein X7 and X8 are independently CH2, O, NH or S; and
c is an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 1, 2, 3, 4, 5 or 6;
(4)
wherein X9 is O, CH2, NR5, S(O), SO2, SO2O, OSO2 or OSO2O;
R5 is H, C1-4alkyl or C(O)C1-4alkyl; and
d is an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 1, 2, 3, 4, 5 or 6; or
(5) biotin or a biotin analog such as:
wherein e and f are, independently, an integer from 0 to 10, 1 to 15, 1 to 10, 1 to 8, or 1, 2, 3, 4, 5 or 6.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the ALD comprises an electrophilic functional group that reacts with an amino acid nucleophile in a nucleophilic substitution reaction.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the electrophilic functional group in the ALD comprises an imidazole group having the following structure:
wherein
X10 is S, O or NR6;
X11 is O or NR7; and
R6 and R7 are independently H or C1-4alkyl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L1 and L2, are independently, C1-20 alkylene, optionally interrupted by triazolyl and/or one or more heteromoieties selected from O, S, S(O), SO2, OSO2, SO2O, OSO2O, NR8, C(O), NHC(O) and C(O)NH, wherein R8 is H or C1-4alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein L1 and L2 are independently, a group having the following structure:
wherein, g, h, i, j, k, p, q, r and s are, independently, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

### Claim 12 (depends on 1)

The compound of claim 1 having the following structure:
wherein
R is TBD.

### Claim 13 (depends on 1)

The compound of claim 1 which is:
Compound
Example
I.D.
#
Structure
I-1 CIR 1
1
I-2 CIR 2
2
I-3 CIR 3
3
I-4 CIR 4
4
I-5 CIR 5
5
or a pharmaceutically acceptable salt and/or solvate thereof.

### Claim 14 (depends on 1)

A composition comprising the compound of claim 1 and a carrier.

### Claim 15 (depends on 1)

A method for labelling an antibody for detection, either in a biological sample or in a subject, comprising administering an effective amount of the compound of claim 1, wherein R is a DMD, to the biological sample or subject.

### Claim 16 (depends on 1)

A method for recruiting an antibody for immunotherapy, either in a biological sample or in a subject, comprising administering an effective amount of the compound of claim 1 wherein R is a TBD, to the biological sample or subject.

### Claim 17 (depends on 1)

A method for recruiting an antibody and targeting a cell for provoking an immune response to the cell, either in a biological sample or in a subject, comprising administering an effective amount of the compound of claim 1 wherein R is a TBD, to the biological sample or the subject.

### Claim 18 (depends on 1)

A method for binding tumor antigens in a cell, either in a biological sample or in a subject, comprising administering an effective amount of the compound of claim 1 wherein R is a TBD, to the biological sample or the subject.

### Claim 19 (depends on 1)

A method for provoking cellular phagocytosis of a target cell, either in a biological sample or in a subject, comprising administering an effective amount of the compound of claim 1 wherein R is a TBD, to the biological sample or the subject.

### Claim 20 (depends on 1)

A method of treating a disease, disorder or condition that is treatable by provoking an immune response, comprising administering a therapeutically effective amount of the compound of claim 1 wherein R is a TBD, to a subject in need thereof, wherein the disease, disorder or condition treatable by provoking an immune response is cancer.
